PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT04305587
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
- Conditions
- Non-Small-Cell Lung CancerPancreatic CancerCachexiaColorectal Cancer
- Interventions
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT04299048
- Locations
- 🇺🇸
SCL Health Cancer Centers of Colorado - St. Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States
🇺🇸American Oncology Partners of Maryland, PA, Germantown, Maryland, United States
🇺🇸Tallahassee Memorial Healthcare Cancer Center, Tallahassee, Florida, United States
Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B
- Conditions
- Hemophilia B
- Interventions
- Biological: Nonacog alfa
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT04286412
- Locations
- 🇮🇳
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳K.J. Somaiya Hospital and Research Centre, Mumbai, Maharashtra, India
🇮🇳Christian Medical College and Hospital, Ludhiana, Punjab, India
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Other: PlaceboGenetic: PF-06939926
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 114
- Registration Number
- NCT04281485
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Arkansas Children's, Little Rock, Arkansas, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV
- Conditions
- RSV InfectionStem Cell Transplant ComplicationsLower Resp Tract Infection
- Interventions
- Drug: RV521 oral tabletDrug: Placebo oral tablet
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04267822
This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1226
- Registration Number
- NCT04267614
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04266509
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids
- Conditions
- Healthy Female Volunteers
- Interventions
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT04267250
- Locations
- 🇺🇸
Quotient Sciences Screening Office, Coral Gables, Florida, United States
🇺🇸Quotient Sciences-Miami, Miami, Florida, United States
A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day
- Conditions
- Arthritis Rheumatoid
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 298
- Registration Number
- NCT04267380
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Renal Impairment Study of PF-06700841
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT04260464
- Locations
- 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami, Florida, United States
🇺🇸University of Miami Division of Clinical Pharmacology, Miami, Florida, United States